CF
RXRX icon

Centaurus Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Centaurus Financial’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63K Hold
17,165
– – ﹤0.01% 1108
2026
Q1 		$53K Hold
17,165
– – ﹤0.01% 1050
2025
Q4 		$70K Buy
17,165
+400
+2% +$1.98K ﹤0.01% 1037
2025
Q3 		$82K Buy
16,765
+2,100
+14% +$11K ﹤0.01% 1026
2025
Q2 		$74K Buy
14,665
+3,555
+32% +$17.5K ﹤0.01% 955
2025
Q1 		$59K Buy
11,110
+336
+3% +$2.45K ﹤0.01% 887
2024
Q4 		$73K Hold
10,774
– – ﹤0.01% 861
2024
Q3 		$71K Buy
+10,774
New +$77.2K ﹤0.01% 832
2023
Q3 		– Sell
-13,242
Closed -$99K – 797
2023
Q2 		$99K Buy
13,242
+2,219
+20% +$15.5K 0.01% 734
2023
Q1 		$74K Hold
11,023
– – 0.01% 875
2022
Q4 		$85K Buy
11,023
+1,000
+10% +$9.81K 0.01% 810
2022
Q3 		$107K Hold
10,023
– – 0.01% 793
2022
Q2 		$82K Buy
+10,023
New +$67.1K 0.01% 810

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Centaurus Financial's RXRX Position: Q2 2026 in Review

Centaurus Financial held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 17,165 shares worth $63K. The position accounts for ﹤0.01% of the portfolio, ranked #1108.

Centaurus Financial first reported a position in RXRX in Q2 2022 and has held it in 13 quarters since. The position peaked at $107K in Q3 2022. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Centaurus Financial held 17,165 shares of Recursion Pharmaceuticals worth $63K as of Q2 2026.
  • Centaurus Financial left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Centaurus Financial's portfolio in Q2 2026, its #1108 holding.
  • Centaurus Financial first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 13 quarters since.
  • Centaurus Financial's Recursion Pharmaceuticals position peaked at $107K in Q3 2022.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Centaurus Financial's 13F filing for Q2 2026, filed 17 Aug 2026.